摘要目的 评估紫杉醇药物涂层球囊治疗症状性下肢动脉硬化性闭塞症的有效性和安全性.方法 对解放军总医院血管外科2013年10月至2014年6月应用紫杉醇药物涂层球囊(DCB)诊治的18例下肢动脉硬化闭塞症患者的临床数据进行回顾分析.18例患者中,男性13例,女性5例,平均年龄(65±7)岁,卢瑟福分级为3～5级.术后3、6个月进行随访,主要随访项目为晚期管腔丢失、靶病变再狭窄率、临床驱动的靶病变再次血运重建率(TLR),以及围手术期及术后6个月的严重临床事件.结果 纳入研究的病变平均长度为(138±91)mm,慢性闭塞性病变所占比例为9/18,支架内再狭窄比例为2/18.手术技术成功比例为18/18.术后6个月,晚期管腔丢失为(0.1±0.9)mm,靶病变再狭窄比例为2/14,临床驱动的靶病变再次血运重建率为0.未发生死亡和截肢等严重不良事件.结论 紫杉醇DCB在治疗下肢动脉硬化性闭塞症方面安全性可靠,能降低术后6个月的远期管腔丢失、再狭窄率和临床驱动的靶病变再次血运重建率.

abstractsObjective To evaluate the safety and efficacy of the drug coated balloon(DCB)with paclitaxel in patients with symptomatic peripheral artery disease(PAD).Methods The clinical data of 18 patients,who were diagnosed as PAD and treated with DCB from October 2013 to June 2014 in Department of Vascular Surgery,People's Liberation Army General Hospital,were retrospectively analyzed.Thirteen male and 5 female patients were in the series,the mean age of the patients was(65±7)years,and the Rutherford's categories were level 3 to 5.Patients were followed up at 3-and 6-month postoperative.The main efficacy end point were late lumen loss(LLL),rate of restenosis and clinically driven target lesion revascularization(TLR).Meanwhile,the clinical events were recorded.Results Mean lesion length,the percentage of total occlusions and the percentage of in-stent restenosis were(138±91)mm,9/18 and 2/18,respectively.Rate of technical success was 18/18.At 6-month postoperative,LLL,rate of restenosis and TLR were(0.1±0.9)mm,2/14 and 0,respectively.There was no deaths or no amputations.Conclusion DCB with paclitaxel is safe in patients with PAD,and associated with reductions in LLL,restenosis and clinically driven TLR 6-month postoperative.